in which

X represents an oxygen atom or a group of formula NZ in which Z represents a hydrogen atom or a (C_1-C_6)alkyl group,

n represents a number 0, 1 or 2, and

R_1, R_2, R_3, R_4 and R_5 each represent, independently of each other, a hydrogen or halogen atom or a trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, phenoxy or phenyl group optionally substituted with a halogen atom or a trifluoromethyl, cyano, hydroxyl, (C_1-C_6)alkyl or (C_1-C_6)alkoxy group, or alternatively R_2 and R_3 together form a group of formula $-OCH_2O-$ or $-CH_2CH_2CH_2CH_2-$, in the form of a base or of an addition salt with an acid.

3. (amended) A pharmaceutical composition comprising a compound according to Claim 1, combined with an excipient.

Please cancel claim 2.

Please add the following new claims:

4. (added) A compound according to claim 1 wherein X is O, NH or $NHCH_3$; n is 0 or 1; R_1 is hydrogen, bromo, methyl or methoxy; R_2 is hydrogen, methyl, methoxy, trifluoromethyl, fluoro or chloro; R_3 is chloro, bromo, methyl, methoxy, nitro, fluoro, hydrogen, phenyl, trifluoromethoxy or phenoxy; or R_2 and R_3 together form a group of the formula $-OCH_2O-$ or $-CH_2CH_2CH_2CH_2-$; R_4 is hydrogen; and R_5 is hydrogen or methoxy; in the form of a base or of an addition salt with an acid.

5. (added) A method for the treatment or prevention of disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

6. (added) A method for the treatment or prevention of disorders linked to nicotinic receptor dysfunction which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.